Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx

Favorable safety and tolerability were demonstrated in hypertriglyceridemia patients in the study Primary and key secondary endpoints were met with significant reduction in apoC-III and triglyceride levels More than 90% of patients achieved serum triglycerides ≤ 150 mg/dL at the highest monthly dose BOSTON and CARLSBAD, Calif., Jan. 22, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive topline results from the Phase 2 study of AKCEA-APOCIII-LRx in the treatment of patients with hypertriglyceridemia who are at risk for or have established cardiovascular disease (CVD). The study met the primary endpoint of significant triglyceride lowering and multiple secondary endpoints with a favorable safety and tolerability profile.

The release as fetched from its publisher. ionis.com ↗